Helus Pharma Inc. has announced a change in ownership involving Mark Lawson, who has recently become a director of the company. This update is significant as it highlights the company's ongoing developments in the pharmaceutical preparations sector.
According to the recent SEC filing dated October 23, 2026, Lawson holds a total of 160,026 shares in Helus Pharma. This total includes 3026 shares owned directly by Lawson and an additional 157,000 shares held indirectly through Four Paths Partners Ltd., a corporation owned and controlled by him.
Background
Helus Pharma Inc. is a company classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol HELP. It is categorized as an emerging growth company, indicating its focus on innovation and growth within the pharmaceutical sector.
What the Filing Says
The SEC filing, identified by accession number 0000912282-26-001380, outlines the ownership details of Mark Lawson. It states, "Lawson holds a total of 160,026 shares, including both direct and indirect ownership." This ownership change is particularly noteworthy as it reflects the confidence of the company's leadership in its future prospects.
Impact
This change in ownership may affect various stakeholders, including current investors and potential partners. The increase in shares held by a director like Lawson could signal a positive outlook for Helus Pharma, potentially influencing investor sentiment and company strategy.
What's Next
The filing does not say what happens next.